Abgenix is involved in cancer research and the development of drugs for various health challenges, including pancreatic cancer and tuberculosis, as self-described.

Abgenix

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Metric
Company Name	Abgenix	HBM Holdings Limited
Symbol		2.14K
MSH ID	COM:ABGENIX	COM:HARBOURBIOMED
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Biotechnology
Country	US	CN
Stage		Series C
Employee Count		177
Website	abgenix.com	harbourbiomed.com
LinkedIn	abgenix
Founders

Metric
Market Cap		131.38M
Enterprise Value
Monthly Web Traffic	99	603
Web Traffic Growth		-0.14
Valuation
Raised Capital		102.80M

Metric
Revenue		89.50M
Revenue (LTM)
Revenue (NTM)
Gross Profit		87.47M
EBITDA		26.65M
Operating Income		21.83M
Net Income		22.80M
EPS		0.03
Diluted EPS		0.03
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		1.00
Operating Profit Margin		0.28
EBITDA Margin		0.30
Net Profit Margin		0.31
Return on Equity		0.21
Return on Assets		0.10
Return on Capital Employed		0.13

ABGE

COM:ABGENIX

Abgenix

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-1.03
P/B Ratio		1.52
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		2.57
EV Multiple		12.92

Metric
Days Sales Outstanding
Days Payables Outstanding		61.85K
Days Inventory Outstanding		4.29K
Operating Cycle		4.34K
Cash Conversion Cycle		-536.87
Asset Turnover		0.39

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt		0.32
Operating Cash Flow/Sales		0.29
Free Cash Flow Yield		-0.76

Metric
Cash & Equivalents		140.32M
Accounts Receivable
Inventory		1
Goodwill
Debt to Capitalization		0.45
Debt to Assets		0.39
Current Ratio		2.79
Quick Ratio		3.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.14
R&D to Revenue		3.32
SG&A to Revenue		0.25